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While the aberrant translocation of the mixed-lineage leukemia (MLL) gene drives pathogenesis of acute myeloid
leukemia (AML), it represents an independent predictor for poor prognosis of adult AML patients. Thus, small
molecule inhibitors targeting menin-MLL fusion protein interaction have been emerging for the treatment of MLL-
rearranged AML. As both inhibitors of histone deacetylase (HDAC) and menin-MLL interaction target the transcription-
regulatory machinery involving epigenetic regulation of chromatin remodeling that governs the expression of genes
involved in tumorigenesis, we hypothesized that these two classes of agents might interact to kill MLL-rearranged (MLL-r)
AML cells. Here, we report that the combination treatment with subtoxic doses of the HDAC inhibitor chidamide and the
menin-MLL interaction inhibitor MI-3 displayed a highly synergistic anti-tumor activity against human MLL-r AML cells
in vitro and in vivo, but not those without this genetic aberration. Mechanistically, co-exposure to chidamide and MI-3 led
to robust apoptosis in MLL-r AML cells, in association with loss of mitochondrial membrane potential and a sharp
increase in ROS generation. Combined treatment also disrupted DNA damage checkpoint at the level of CHK1
and CHK2 kinases, rather than their upstream kinases (ATR and ATM), as well as DNA repair likely via homologous
recombination (HR), but not non-homologous end joining (NHEJ). Genome-wide RNAseq revealed gene expression
alterations involving several potential signaling pathways (e.g., cell cycle, DNA repair, MAPK, NF-κB) that might account
for or contribute to the mechanisms of action underlying anti-leukemia activity of chidamide and MI-3 as a single
agent and particularly in combination in MLL-r AML. Collectively, these findings provide a preclinical basis for further
clinical investigation of this novel targeted strategy combining HDAC and Menin-MLL interaction inhibitors to improve
therapeutic outcomes in a subset of patients with poor-prognostic MLL-r leukemia.
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Cytogenetic abnormalities are closely associated with clin-
ical features and therapeutic responses in acute myeloid
leukemia (AML) [1]. Chromosome 11q23 translocations
occur in 10% of adult AML patients, while being even
more frequent in pediatric cases (35%) [2–4]. In AML,
most of 11q23 translocations led to fusion proteins involv-
ing the mixed lineage leukemia (MLL) gene that encodes
histone lysine methyltransferase 2A (KMT2A) [5], of
which more than 70 translocation partners of MLL have
been characterized so far [6, 7]. The clinical outcome of
patients carrying MLL-rearrangement who often suffer
from either failure of induction therapy or disease relapse
remains extremely poor, while the response rate reported
in adult MLL-rearranged (MLL-r) AML is approximately
40% [8]. Although dose intensification of chemotherapy
might reduce the risk of relapse, it is however associated
with the long-term adverse effects and a high rate of
treatment-related mortality [9]. Therefore, a more effect-
ive and less toxic therapy is urgently needed to treat this
subset of AML with poor prognosis.
Chidamide, a novel histone deacetylase (HDAC) in-
hibitor of the benzamide class that specifically inhibits
HDAC1-3, has approved by the Chinese FDA for treat-
ment of relapsed or refractory peripheral T cell lymph-
oma (PTCL) [10, 11]. Recently, several groups including
ours have demonstrated that chidamide displays promis-
ing activity against various cancer types, especially
hematological malignancies including AML [12–14]. It
has been well established that HDACs, of which at least
18 members have been characterized, play the key roles
in the epigenetic regulation of gene expression through
chromatin remodeling by inhibiting histone deacetyla-
tion [15, 16]. Among them, HDAC1, 2 and 3 are fre-
quently overexpressed in human leukemia [17], which
could interact with MLL fusion partners and result in
aberrant regulation of chromatin remodeling and thus
the expression of tumor-driven genes [18]. Earlier stud-
ies have demonstrated that chidamide synergizes with
conventional chemotherapeutic agents in human
leukemia cells by disrupting cell cycle progression and
DNA damage responses, as well as promoting ROS-
dependent apoptosis [19]. However, because the single-
agent activity of chidamide towards relapsed or refrac-
tory AML appears not to be satisfied, the combination
strategy involving chidamide thus warrants investigation
in this disease.
Menin, which is encoded by the multiple endocrine
neoplasia 1 (MEN1) gene, is known to interact directly
with the N-terminal domain of MLL. This interaction is
required for the activation of target gene expression by
the MLL-fusion proteins, thereby critical for their cap-
ability to mediate transformation [20]. Menin is also in-
volved in DNA damage response (DDR), particularlyDNA repair. For example, Menin is accumulated with
CHK1 at the sites of double-strand break (DSB) [21].
Thus, the menin-MLL interaction has recently been con-
sidered as a potential therapeutic target in MLL-r
leukemia [22]. In this context, it raises a possibility that
the specific inhibitors targeting the menin-MLL inter-
action may block MLL fusion protein-mediated leukemic
transformation by down-regulating the expression of
MLL target genes, an event that is required for the onco-
genic activity of MLL fusion proteins. Indeed, this type
of small molecule inhibitors has displayed a single-agent
anti-proliferative activity in vitro and in vivo in a model
of MLL-r leukemia [23]. However, for most targeted
agents, the single-agent therapy is unlikely to be curative
in AML, primarily due to co-existing perturbations in-
volving multiple leukemogenic signaling pathways in this
highly heterogeneous disease. It is therefore anticipated
that menin-MLL interaction inhibitors might be more
effective in rational combination regimens.
To this end, we sought to examine whether and how the
menin-MLL interaction inhibitor MI-3, which acts to in-
hibit transcription of MLL target genes, would interact with
the HDAC inhibitor chidamide, a class of epigenetic agents
that regulate gene expression through chromatin remodel-
ing, in MLL-r AML. Here, we reported that simultaneous
inhibition of both HDAC and MLL-menin interaction ex-
hibits a synergistic cytotoxic activity in vitro specifically
against AML cells carrying MLL-rearrangement. This com-
bination regimen was also active in vivo (e.g., delayed tumor
progression and reduced tumor burden) in an MLL-r AML
xenograft mouse model. Together, these findings argue that
this novel regimen rationally combining the HDAC inhibi-
tor chidamide and the MLL-menin inhibitor MI-3 might
represent a promising option for treatment of MLL-r AML.
Results
Chidamide synergistically interacts with MI-3 to
suppresses the growth of MLL-rearrangement AML cells
We first examined the activity of chidamide and MI-3
alone and in combination to determine whether these
two agents would synergistically interact with each other
in inhibition of MLL-r AML cell viability. To this end,
after exposing to a series of concentrations of chidamide
or MI-3 for 24, 48, and 72 h, viability of MOLM-13 and
MV4-11 cells, both lines carrying MLL-rearrangement,
were determined by the CCK-8 analysis. As shown in
Additional file 1: Figure S1A–D, exposure to either agent
resulted in a marked increase in cytotoxicity towards
these MLL-r AML cells in a dose- and time-dependent
manner. Based on the single-agent activity after treated
for 24, 48, and 72 h, the IC50 values for chidamide and
MI-3 were calculated in MOLM-13 and MV4-11 cells,
respectively (Table 1). Of note, the combined treatment
with subtoxic doses of chidamide and MI-3 (≤ IC50 for
Table 1 IC50 values of chidamide and MI-3 as single agent in
AML cells
Chidamide MI-3
IC50(μM) 95%CI IC50(μM) 95%CI
24 h 8.240 4.868–13.950 53.54 33.920–84.510
MOLM-13 48 h 6.578 4.782–9.050 34.69 23.240–51.790
72 h 1.180 0.332–4.192 13.11 7.502–22.920
24 h 4.623 3.822–5.593 53.72 29.770–96.910
MV4-11 48 h 2.630 1.438–4.810 44.90 39.250–51.370
72 h 2.379 1.274–4.443 15.01 9.520–23.680
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of cell viability in MOLM-13 (Fig. 1a) and MV4-11 cells
(Fig. 1b) at 24, 48, and 72 h. Moreover, the combination
index (CI) < 1.0 indicated a synergistic interaction be-
tween chidamide (1.6–8.2 μM) and MI-3 (10.6–53.5
μM) in MOLM-13 (Fig. 1c), as well as between chida-
mide (0.9–4.6 μM) and MI-3 (10.7–53.7 μM) in MV4-11
(Fig. 1d). Values of fraction affected (Fa) and CI for each
cell line after treatment for 24, 48, and 72 h were pro-
vided in Additional file 2: Table S1, of which the CI
values ranged from 0.4 to 0.8. In contrast, the human
AML cell lines Kasumi-1 and KG1α without MLL-
rearrangement were much less sensitive to this regimen
combining chidamide and MI-3 in the same range of
concentrations (Additional file 1: Figure S2A–C). To-
gether, these results indicate that chidamide synergistic-
ally interacts with MI-3 to reduce the viability of AML
cells carrying MLL-rearrangement. They also raise a
possibility that AML cells carrying MLL-rearrangement
might be particularly susceptible to this combination
regimen.
Co-exposure to chidamide and MI-3 induces apoptosis of
MLL-rearrangement AML cells, in association with
increased ROS generation and mitochondrial injury
To validate the synergistic effect of the regimen combining
chidamide and MI-3 on MLL-r AML cells, the colony for-
mation assay was performed. As shown in Fig. 2a, whereas
chidamide (2.6 μM) and MI-3 (13.9 μM) displayed moder-
ate single-agent activity, a significant reduction in colony
formation was observed in MOLM-13 cells after combined
treatment, compared with these two agents alone. Analo-
gous results were obtained from MV4-11, another MLL-r
AML cells (Additional file 1: Figure S3A). Moreover, flow
cytometry with Annexin V/PI staining was then performed
to examine whether chidamide would interact with MI-3 to
induce apoptosis in MLL-r cells. After exposing to chida-
mide and MI-3 alone or in combination for 48 h, the per-
centage of apoptotic (Annexin V-positive) cells was
significantly increased in MOLM-13 (Fig. 2b) and MV4-11
cells (Additional file 1: Figure S3B), compared to eachsingle agent. As loss of mitochondrial membrane potential
(MMP) plays a crucial role in the initiation of intrinsic
mitochondrion-dependent apoptotic cascade [25], we next
examined the effect of chidamide and MI-3 individually or
in combination on MMP. Consistent with the results for
apoptosis, combined treatment with chidamide and MI-3
also induced loss of MMP, reflected by impaired mitochon-
drial depolarization indicated by markedly decreased fluor-
escence intensity ratio between JC-1 aggregate and
monomer (Fig. 2c and Additional file 1: Figure S3C). To
unveil the potential mechanism underlying the synergistic
interaction between these two agents in the induction of
apoptosis, flow cytometry was carried out to monitor intra-
cellular ROS levels. After co-treated with chidamide and
MI-3 for 48 h, a significant increase in ROS generation was
observed in MOLM-13 (Fig. 2d) and MV4-11 cells (Add-
itional file 1: Figure S3D), compared to treatment with each
single agent. Together, these results suggest that chidamide
interacts synergistically with MI-3 to induce apoptosis of
AML cells carrying MLL-rearrangement via promotion of
ROS production and mitochondrial damage.
Co-treatment with chidamide and MI-3 alters genome-
wide gene expression in MLL-rearrangement AML cells
Anti-tumor activity of both HDAC inhibitor and menin-
MLL interaction inhibitor involves transcriptional regu-
lation of gene expression [26–29]. To further understand
the mechanism of action underlying the synergistic
interaction between chidamide and MI-3 in AML-
carrying MLL-rearrangement, the RNAseq assay was
then performed to profile genome-wide gene expression
in MOLM-13 cells after treated with chidamide and MI-
3 alone or in combination (see Additional file 2: Table
S2 for a list of all genes). After combined treatment with
chidamide and MI-3 for 24 h (Fig. 3a) and 48 h (Fig. 3b),
the KEGG analysis indicated that the most significantly
altered pathways involving cell cycle, DNA replication,
and several DNA repair mechanisms [e.g., homologous
recombination (HR), nucleotide excision repair, base ex-
cision repair, mismatch repair, and Fanconi anemia
pathway]. Further, the GESA analysis further revealed
that most of these alterations stemmed from chidamide,
rather than MI-3 (Additional file 1: Figure S4A–C).
Moreover, the analysis of the dataset (48 h treatment)
for the significantly downregulated or upregulated tran-
scripts (log2FC ≥ 1, Q value ≤ 0.001) revealed gene ex-
pression profile (GEPs) for chidamide (blue) and MI-3
(yellow) alone or in combination (red) with an overlap
of 635 genes (Fig. 3c). A majority of these overlapped
genes displayed the same trends of expression (i.e., up-
or downregulation) in MOLM-13 cells treated with MI-
3 and chidamide alone or in combination (Fig. 3d).
However, there was a small cluster of 59 genes (indicated
by square in Fig. 3d) that were differentially expressed in
Fig. 1 The HDAC inhibitor chidamide synergistically interacts with the menin-MLL interaction inhibitor MI-3 to inhibit cell viability in MLL-r AML cells. a, b Human
MLL-rearranged AML cell lines MOLM-13 (a) and MV4-11 cells (b) were exposed to the indicated concentrations (μM) of chidamide ± MI-3 (μM) for 24, 48, and 72
h, after which cell viability was examined using the CCK-8 assay. Values indicate mean ± SEM for at least three independent experiments performed in triplicate.
*P < 0.05, **P < 0.01, and ***P < 0.001 for comparison with each single agent. c, dMOLM-13 (c) and MV4-11 (d) cells were treated as described in Additional file
2: Supplemental Table 1, followed by the analysis of cell viability as above, after which the CompuSyn analysis was performed to determine whether the
interaction between these two agents is synergistic (CI value < 1.0)
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Fig. 2 Co-treatment with chidamide and MI-3 induces robust apoptosis, in association with increased ROS generation and loss of mitochondrial
membrane potential. a MOLM-13 cells were treated with 2.63 μM chidamide ± 13.88 μM MI-3 for 48 h, followed by the colony formation assay.
b, c MOLM-13 cells were treated as above, after which flow cytometric analysis was performed to determine percentage of Annexin V+ apoptotic
cells (b) and cells with loss of mitochondrial membrane potential (c). a–c The representative results were shown (left), and the data for at least
three independent experiments was presented as bar graphs (right). d In parallel, intracellular ROS levels were measured by flow cytometry using
the Reactive Oxygen Species Assay Kit. Values indicate mean ± SEM for at least three independent experiments performed in triplicate (***P < 0.001)
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chidamide alone or in combination (upregulation; Fig. 3e).
The gene ontology (GO; Additional file 1: Figure S4D) and
KEGG (Additional file 1: Figure S4E) analyses revealed that
these genes were associated with several key survival signal-
ing pathways (e.g., MAPK, NF-κB). They also suggested that
cytokine signaling pathways (e.g., TNF), which is essential for
the inflammatory reaction [30] and known to be involved in
single-agent activity of chidamide [31], might also be in-
volved in the interaction between chidamide and MI-3 in
MLL-r AML cells. In this context, the real-time PCR analysis
was performed to validate the expression of IL1B that en-
codes the pro-inflammatory cytokine IL-1β, a representative
gene selected from 59 overlapping genes described in Fig. 3e.
Consistent with the RNAseq results, exposure of MOLM-13
cells to chidamide in the absence or presence of MI-3 re-
sulted in a marked increase in expression of IL1B (Fig. 3f).
However, qPCR failed to detect whether MI-3 alone down-
regulated the expression of IL1B, due to its low basal level in
untreated cells. Together, these results suggest that themechanism of action underlying anti-leukemic activity of the
combination treatment with chidamide and MI-3 might in-
volve DDR in MLL-r AML cells. They also raise the possibil-
ity that co-administration of chidamide might reactivate a set
of genes that are silenced by MI-3.
Co-treatment with chidamide and MI-3 disrupts DNA
damage response and results in DNA damage in AML-
carrying MLL-rearrangement
We then performed a gene set enrichment analysis
(GSEA) of differentially expressing genes in MOLM-13
cells after treated with chidamide and MI-3 alone or in
combination. Four genes were identified, which met both of
the following criteria, including (a) at least 2-fold downregu-
lation by chidamide or MI-3 and (b) at least 4-fold down-
regulation by combined treatment. These genes included
SULT1A3 (sulfotransferase 1A3/1A4), AEBP1 (transcrip-
tional repressor), CCNE2 (cyclin E2), and ATF5 (transcrip-
tion factor; Fig. 4a and Additional file 1: Figure S5). Among
them, SULT1A3 is known to catalyze sulfation of
Fig. 3 RNA sequencing reveals genome-wide gene expression profiles of MOLM-13 cells treated with chidamide and MI-3 alone or in combination. a, bMOLM-
13 cells were treated with 2.6 μM chidamide ± 13.9 μMMI-3 for 24 h (a) or 48 h (b), after which total RNA was extracted and subjected to whole exome RNAseq
that was performed in triplicate for each condition. The KEEG analysis reveals the annotations of the most enriched pathways of differentially expressing genes
after combined treatment for 48 h, compared to untreated control. c–e Alternatively, a Venn diagram shows the number of genes and their relationship that
were differentially expressed (log2FC ≥ 1, Q value ≤ 0.001) after treatment with chidamide and MI-3 alone or in combination, compared to untreated control (c).
A heatmap shows hierarchical clustering of 635 genes significantly affected by all three treatments, including chidamide, MI-3, and combined treatment (d). A
heatmap shows hierarchical clustering of 59 genes (indicated by square in panel B) that were upregulated by chidamide and combined treatment, but
downregulated by MI-3 (e). f Real-time PCR analysis was performed to monitor expression of IL1B, one of 59 genes shown in panel c, in MOLM-13 cells after
treated with chidamide ± MI-3 for 48 h. The reaction was carried out in triplicate and relative expression levels were calculated as 2−△△CT after normalization to β-
actin. Values indicate mean ± SEM for at least three independent experiments performed in triplicate (**P < 0.01, NS = not significant)
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33]. Since the RNAseq analysis after treatment for either 24
or 48 h (Additional file 1: Figure S4A and S4B) suggested a
potential role of DNA damage response (DDR) in the anti-
tumor activity of the regimen combining chidamide and
MI-3, qPCR analysis was performed to validate expression
of SULT1A3 as representative. Consistent with the results
of the RNAseq analysis (Fig. 4a), exposure to either chida-
mide or MI-3 was able to downregulate SULT1A3 expres-
sion, while the combination treatment resulted in a greater
reduction in its expression (Fig. 4b). In this context, western
blot analysis was further carried out to examine the DDR
signaling pathway, which is orchestrated by ATM and ATR
as well as their key downstream checkpoint kinases CHK1
and CHK2. As shown in Fig. 4c and Additional file 1: Figure
S6, exposure to chidamide in the presence or absence of
MI-3 led to increased acetylation of histone H3 in various
AML cell lines, due to inhibition of its deacetylationcatalyzed by HDACs. Interestingly, treatment with MI-3
also modestly increased H3 acetylation in MOLM-13 cells
(Fig. 4c), but not in MV4-11 or Kasumi-1 cells (Additional
file 1: Figure S6), suggesting a cell line-specific
phenomenon. Notably, combined treatment with these two
agents clearly induced phosphorylation (activation) of both
ATM and ATR. In contrast, whereas exposure to either
MI-3 or in a lesser extent chidamide attenuated phosphoryl-
ation (activation) of both CHK1 and CHK2, these events
were almost completely inhibited by co-administration of
these two agents (Fig. 4c). Combined treatment also mark-
edly downregulated the expression of Rad51, an important
DNA repair protein [34], while did not affect the levels of
another DNA repair protein KU70. As a consequence, the
combination treatment induced robust DNA damage, man-
ifested by a sharp increase in expression of γH2A.X (Fig.
4c), a marker of DNA double-strand break [35]. Together,
these results suggest that disruption of the DNA damage
Fig. 4 Combined treatment with chidamide and MI-3 disrupts DNA damage response. a A heatmap shows hierarchical clustering of four genes,
among 635 genes described in Fig. 3a, that were downregulated ≥ 2-folds by chidamide or MI-3 alone and ≥ 4-fold by these two agents in
combination. b Real-time PCR analysis was performed to validate the expression of SULT1A3, one of 4 genes shown in panel a, in MOLM-13 cells
treated with chidamide ± MI-3 for 48 h. The reaction was carried out in triplicate and relative expression levels were calculated as 2−△△CT after
normalization to β-actin. Values indicate mean ± SEM for at least three independent experiments performed in triplicate (**P < 0.01 and ***P <
0.001). c MOLM-13 cells were exposed to chidamide ± MI-3 for 48 h, after which western blot analysis was performed to monitor the expression
of the indicated proteins involved in DNA damage checkpoint and DNA repair, as well as γH2A.X, a marker for DNA double-strand breaks
Ye et al. Clinical Epigenetics          (2019) 11:137 Page 7 of 14checkpoint through inactivation of CHK1 and CHK2, rather
than their upstream kinases ATM and ATR, as well as
interfere with the DNA repair machinery by downregulating
DNA repair proteins (e.g., Rad51), might account for or at
least contribute to the synergistic interaction between chi-
damide and MI-3 in AML cells carrying MLL-
rearrangement.
The regimen combining chidamide and MI-3 is active
in vivo in a xenograft model of AML-carrying MLL-
rearrangement
Last, anti-tumor activity of the regimen combining chida-
mide and MI-3 was examined in a mouse xenograft model
established by subcutaneous inoculation with MLL-r
MOLM13 cells. After 3 days, mice were randomly divided
into four groups, including vehicle control, chidamide,
MI-3, and the combination treatment (Fig. 5a). Although
a moderate reduction in body weight was observed at days10–12 after treatment with chidamide and MI-3 in com-
bination, but rapidly recovered at day 14 (Fig. 5b). Other-
wise, no other signs of notable toxicity were observed.
Significantly, combined treatment with chidamide and
MI-3 resulted in a marked reduction in tumor burden,
reflected by decreased volume and weight of tumor
masses, compared to vehicle control as well as each indi-
vidual agent (Fig. 5c–e). These results were also confirmed
by histological examination (Fig. 5f). Together, these find-
ings indicate that the combination regimen of chidamide
and MI-3 is effective in vivo against MLL-r AML, while
well tolerated.
Discussion
AML is a highly heterogeneous disease, of which 35–
50% in infant and ~ 10% in adult carry MLL-
rearrangement [2–4], a genetic abnormality that leads to
various MLL fusion proteins with strong oncogenic
Fig. 5 Co-administration of chidamide and MI-3 suppresses tumor growth in a xenograft model of MLL-r AML. a A scheme for the animal study
that are described in detail in the “Materials and methods” section. b Mice were weighed daily after tumor cell inoculation. c–e Mice were
sacrificed after drug treatment for 14 days, and then the images of mice and tumors were captured (c). Weight (d) and volume (e) of tumors
were measured and calculated. Values indicate mean ± SEM for 6 mice/each group (**P < 0.01, ***P < 0.001). f Tumors sections were prepared
and stained by H&E for histological examination
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sive and often associated with poor prognosis, primarily
due to the lack of effective treatment [37, 38]. Menin
acts as a key cofactor of oncogenic MLL fusion proteins
[39]. For example, menin is required for the mainten-
ance of HOX gene expression mediated by MLL fusion
proteins [28]. In this context, small molecule inhibitors
targeting the interaction between menin and MLL fusion
proteins are recently emerging to treat AML carrying
MLL-rearrangement. Indeed, these inhibitors are able to
reverse MLL fusion protein-mediated leukemic trans-
formation via downregulation of HOX genes. Therefore,
this novel class of anti-cancer agents has recently
attracted a lot of interests in treatment of poorly prog-
nostic AML-bearing MLL-rearrangement. However, al-
though earlier studies have demonstrated promising
activity of several menin-MLL interaction inhibitors
in vivo in MLL-r AML xenograft mouse models, thera-
peutic responses remain limited. To this end, ourobservations in the present study indicate that a rationale-
based regimen combining these inhibitors (e.g., MI-3) and
HDAC inhibitors (e.g., chidamide) might display signifi-
cantly increased anti-tumor activity towards AML carry-
ing MLL-rearrangement, compared to each single agent,
at least in the preclinical setting.
The rationale for combining inhibitors of HDAC and
menin-MLL interaction is laid on their properties target-
ing transcription-regulatory machinery. On the one
hand, HDACs regulate gene expression via chromatin
remodeling [26]. They function to “tighten” or “close”
chromatin structure by deacetylating nucleosomal his-
tones (e.g., H3 and H4) to reduce the accessibility of
transcription factors [27]. In contrast, HDAC inhibitors
act to “loose” or “open” chromatin structure through in-
hibition of histone deacetylation by HDACs, which al-
lows transcription factors to access and binding to
promoters of target genes, thereby initiating and pro-
moting their expression [41–43]. Notably, the implication
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HDAC inhibitors to treat this disease [44, 45]. Moreover,
leukemia-carrying MLL-rearrangement is highly susceptible
to HDAC inhibition [46]. On the other hand, MLL methyl-
ates histone H3 to upregulate expression of target genes, in-
cluding several HOX genes [28, 29]. In MLL-rearranged
AML, certain MLL fusion proteins display enhanced activ-
ity to promote gene transcription by recruiting a transcrip-
tional activation complex known as P-TEFb that consists of
CDK9 and cyclin T1 [47, 48]. The leukemia-driving activity
of MLL fusion proteins relies on their interaction with
menin, a protein encoded by the multiple endocrine neo-
plasia (MEN1) gene [49]. Menin directly binds to the N-
terminal domain of MLL in virtually all MLL fusion pro-
teins, an event that is essential for leukemic transformation
[50]. In this context, small molecule inhibitors (e.g., MI-3)
specifically targeting the interaction between menin and
MLL fusion proteins have recently been emerging to treat
acute leukemias harboring MLL-rearrangement [51].
Therefore, as the mechanisms of action for both HDAC
and menin-MLL interaction inhibitors involve
transcription-regulatory machinery, a possibility then arose
that these two classes of agents may interact synergistically
in MLL-rearranged leukemia. Indeed, the results of the
present study demonstrated a highly synergistic interaction
between chidamide and MI-3 at their subtoxic dose ranges
in human AML cells carrying MLL-rearrangement (e.g.,
MOLM-13 and MV4-11), but not in cells that did not har-
bor this genetic abnormality. The anti-tumor activity of this
combination regimen was further validated in vivo in a
mouse xenograft model of human MLL-r AML. In
addition, marked inhibition of the colony-forming activity
of MLL-r AML cells by the combination treatment raises
the possibility that this regimen might also suppress self-
renewal of leukemic stem cells.
Because both HDAC and menin-MLL interaction
inhibitors target general transcription-regulatory ma-
chinery [40, 52], they may thus affect genome-wide ex-
pression of numerous target genes. To this end, the
RNAseq analysis revealed that exposure to chidamide
and MI-3 alone influenced expression of 3665 and 1041
genes in MLL-r AML cells, respectively, while combined
treatment resulted in altered expression of 4050 genes.
Moreover, although treatment with chidamide and MI-3
alone or in combination led to global changes in gene
expression, a set of 635 genes that were overlapped
among these three treatment conditions was observed.
Among them, a small cluster of 59 genes was oppositely
regulated by MI-3 and chidamide (either alone or in
combination). The functions of these differentially
expressed genes were involved in several signaling pathways
(e.g., MAPK, NF-κB) crucial for tumor cell survival and
proliferation [30, 53]. In addition, the roles of these genes
also involved the inflammatory responses (e.g., the TNF-signaling pathway). However, the effect of the combination
treatment on inflammatory responses (e.g., expression of
IL-1β, a well-established marker of inflammation) [54, 55]
seems to solely stem from chidamide, rather than MI-3,
thereby arguing against that this effect represents the pri-
mary mechanism for the high synergy between these two
agents. Therefore, an alternative strategy for further analysis
of this RNAseq dataset might be required to identify other
candidate pathways and targets responsible for or involved
in the synergistic interaction between chidamide and MI-3
in MLL-r AML.
In the present study, bulk evidence indicates that the
anti-tumor activity of the regimen combining chidamide
and MI-3 towards MLL-r AML was associated with in-
duction of apoptosis, primarily via the intrinsic
mitochondrion-dependent pathway [36, 56]. First, while
exposure to chidamide led to the loss of mitochondrial
membrane potential, reflecting mitochondrial injury [57,
58], this event was significantly potentiated by co-
administration of MI-3. Second, as mitochondria are
considered as the main source of ROS in the cell [59,
60], a robust increase in ROS generation was observed
in MLL-r AML cells exposed to both chidamide in the
presence of MI-3. Last, flow cytometric analysis revealed
that whereas treatment with either chidamide or MI-3
moderately increased apoptotic (Annexin V-positive)
cells, this event was dramatically potentiated after co-
administration of these two agents. Therefore, these ob-
servations argue strongly that chidamide might interact
with MI-3 to activate the mitochondrion-related apop-
totic signaling cascade. However, due to the multifacial
functions of HDAC inhibitors, a caveat that other mech-
anisms might also contribute to the anti-leukemia effect
of chidamide alone and even in combination with MI-3
in MLL-r AML cells could not be excluded.
Both menin and HDAC also play important roles in
DNA damage response (DDR), particularly including
DNA damage checkpoint and DNA repair [61, 62].
Moreover, it has been reported that HDAC or menin-
MLL interaction inhibitors could induce apoptosis
through interference with cytoprotective DDR [61, 63].
Thus, it raises a possibility that these two classes of
agents may interact to disrupt DDR and therefore trigger
DNA damage in MLL-r AML cells. Indeed, co-exposure
to chidamide and MI-3 led to a sharp increase in S139
phosphorylation of H2A.X (termed γH2A.X), a well-
established marker for DNA double-strand breaks
(DSB). Interestingly, co-administration of chidamide and
MI-3-induced phosphorylation (activation) of ATM and
ATR, two kinases involved in initiation of DDR [64, 65].
However, combined treatment almost completely inhibited
phosphorylation (activation) of CHK1 and CHK2, two key
kinases of DNA damage checkpoint that act as direct
downstream targets of ATR and ATM [66, 67]. Taken
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men appears to target primarily on CHK1 and CHK2, ra-
ther than their upstream kinases (ATR and ATM), while
activation of the latter might reflect a feedback response to
inactivation of CHK1 and CHK2 after co-exposing to chi-
damide and MI-3. In addition, the combined treatment also
downregulated Rad51, a DNA repair protein that plays a
major role in homologous recombination (HR) repair of
DSB [34]. However, it did not affect the levels of Ku70, an-
other DNA repair protein critical for non-homologous end
joining (NHEJ) repair of DSB [68]. These observations sug-
gest that the regimen combining chidamide and MI-3
might selectively target DNA repair via HD, rather than
NHEJ. Interestingly, the GSEA analysis of the RNAseq
dataset identified SULT1A3 as one of four genes that were
downregulated by chidamide and MI-3 alone or in combin-
ation, which was confirmed by real-time PCR analysis.
SULT1A3 encodes an enzyme involved in the metabolism
of nitrotyrosine, while increased levels of nitrotyrosine serve
as a biomarker of oxidative stress that induces DNA dam-
age [32, 33]. Thus, this finding raises the possibility that
SULT1A3 might represent a potential target that links oxi-
dative stress (e.g., ROS) and DNA damage together in
MLL-r AML cells co-treated with MI-3 and HDAC inhibi-
tors. However, further studies are required to address this
possibility.
In summary, the findings of the present study dem-
onstrate a highly synergistic interaction between the
HDAC inhibitor chidamide and the menin-MLL inter-
action inhibitor MI-3 both in vitro and in vivo in
AML cells with MLL-rearrangement. They also pro-
vide evidence for the potential mechanisms underlying
the markedly increased anti-leukemia activity of this
combination regimen, including ROS generation,
apoptosis induction via the mitochondrion-dependent
signaling pathway, and disruption of DDR (e.g., DNA
damage checkpoint and DNA repair via HR). In
addition, the genome-wide gene expression profile
(GEP) by the RNAseq analysis might serve as a re-
source for future studies to identify potential targets
(e.g., SULT1A3) and pathways to further understand
the mechanisms of action for these two classes of
agents in AML carrying MLL-rearrangement. Due to
the current lack of effective therapy for the treatment
of MLL-rearranged AML, the strategy combining
HDAC and menin-MLL interaction inhibitors war-
rants further investigation in this poorly prognostic
subset of AML.Material and methods
Reagents
The HDAC inhibitor chidamide (CS055, purity > 95%)
was kindly provided by Chipscreen Bioscience Ltd.(Shenzhen, China). The MLL-menin interaction inhibi-
tor MI-3 (purity = 99.03%; Cat. No. S7619) was pur-
chased from Selleck Chemicals (Houston, TX, USA).
The reagents were dissolved in dimethyl sulfoxide
(DMSO; Invitrogen, Carlsbad, CA, USA) as 10 mM
stock solution and stored at − 20 oC, which was then di-
luted to the required concentrations with cell culture
medium prior to experiments.Cell culture and sorting
Human AML cell lines MOLM-13 and MV4-11 carrying
MLL-rearrangement were purchased from ATCC
(Rockefeller, MD, USA) and cultured at 37 °C in a 5%
CO2 incubator in Iscove’s modified Dulbecco’s medium
(IMDM) and RPMI-1640 medium (HyClone, Thermo
Scientific, Logan, UT, USA) supplemented with 10%
fetal bovine serum (FBS, Gibco, Thermo Scientific,
Grand Island, NY, USA), respectively. For sorting
CD34+/CD38− cells, cells were stained with hCD34-APC
(eBioscience, Thermo Scientific, San Diego, CA, USA)
and hCD38-PE (eBioscience, Thermo Scientific, San
Diego, CA, USA) for 30 min at 4 °C. After washed twice
with PBS containing 1% FBS, CD34+/CD38− cells were
sorted using FACS Aria IIU (Biosciences, Franklin Lakes,
NJ, USA).Analysis of cell proliferation and viability
Cytotoxicity was determined by using the Cell Count-
ing Kit-8 (CCK-8, Dojindo, Kumamoto, Japan) [24].
Briefly, 2 × 104/well cells were seeded in 100 μl
medium on 96-well plates and treated with indicated
concentrations of chidamide and MI-3 alone or in
combination for 24, 48, and 72 h. The CCK-8 reagent
(10 μl/well) was then added and incubated for add-
itional 2 h, after which the absorbance at 450 nm was
detected by a microplate reader (ELx800, BioTek, Wi-
nooski, VT, USA). The data from three independent
experiments in triplicate was presented as percentage
of viable cells by comparing to untreated control.
IC50 values were determined using the SPSS 20.0
software.Analysis of apoptosis
Cells were cultured and treated chidamide with or with-
out MI-3 for 24, 48, or 72 h as described above, followed
by double staining with Annexin V-FITC and PI
(eBioscience, Thermo Scientific, San Diego, CA, USA)
for 15 min at room temperature in dark as per the man-
ufacturer’s instruction. Cells were then analyzed by flow
cytometry (FACS Fortessa, BD Biosciences, Franklin
Lakes, NJ, USA). The percentage of Annexin V-positive
(apoptotic) cells was determined.
Ye et al. Clinical Epigenetics          (2019) 11:137 Page 11 of 14Analysis of mitochondrial membrane potential
2 × 105/ml cells were seeded in 24-well plates and
treated with chidamide and MI-3 alone or in combin-
ation at indicated concentrations. After 24 h incubation,
cells were harvested and stained with 2 μM Rhodamine
123 (Byeotime, Shanghai, China) for 30 min at 37 oC.
After washed, mitochondrial membrane potential
(MMP) was analyzed by flow cytometry (FACS
Fortessa).Measurement of ROS
Intracellular ROS levels were determined using the Reactive
Oxygen Species Assay Kit (no. S0033, Beyotime, Shanghai,
China) as per the manufacturer’s instruction. Briefly, after
treated with indicated concentrations of chidamide and MI-3
alone or in combination for 24 h, cells were harvested and
stained with 10 μM 2′,7′-dichlorofluorescein diacetate
(DCFH-DA, 1:1000 diluted in RPMI1640) for 20 min at 37
°C. After washed twice, intracellular ROS level was deter-
mined by flow cytometry (FACS Fortessa).Colony formation assay
2×105/well cells at logarithmical growth phase were
seeded in 24-well plates and treated with indicated con-
centrations of chidamide and MI-3 alone or in combin-
ation for 48 h. After washed, 500/well cells were then
cultured in complete methylcellulose medium (R&D Sys-
tems, Minneapolis, MN, USA) in 3.5 cm dishes for 14
days. Colonies consisting of at least 50 cells were
counted and analyzed for colony-forming capability.Western blot analysis
2×105/well cells were treated with chidamide in the ab-
sence or presence of and/or MI-3 for 48 h, and the sub-
jected to western blot analysis using indicated primary
antibodies and secondary HRP-conjugated antibodies (1:
10,000, Abcam, Cambridge, UK). The primary antibodies
included anti-caspase-3 (#9662S), anti-PARP (#9532S),
anti-histone H3 (#4499S), anti-phospho-H3 (#53348S),
anti-γH2A.X (#2577S), anti-RAD51 (#8875S), anti-KU70
(#4588S), anti-STAT3 (#9139 S), anti-Mcl-1 (#94296S),
anti-phospho-p53 (#9286S), anti-p21(#2947S), anti-
phospho-ATM (#5803S), anti-ATM (#2873S), anti-
phospho-ATR (#2835S), anti-CHK1 (#2360), anti-CHK2
(#2662), anti-P-CHK1 (#2197S), and anti-P-CHK2
(#2348S) from Cell Signaling Technology (Boston, MA,
USA). The primary antibodies were diluted with 5% fat-
free milk-TBST. Anti-β-actin (1:1000, Cell Signaling
Technology) was used as loading control. Blots were
then detected using the ECL Western Blotting Detection
Kit (GeneFlow, Staffordshire, UK).RNA sequencing
Cells were incubated with chidamide with or without
MI-3 for 24 or 48 h, after which total RNA was isolated
as described previously [12]. RNA sequencing (RNAseq)
was then carried out via a commercially available service
(service ID# F18FTSSCWLJ1284, BGI, Huada Gene,
Wuhan, China). Briefly, after total RNA was fragmented
into short fragments and mRNA was enriched using
oligo (dT) magnetic beads, followed by cDNA synthesis.
Double-stranded cDNA was purified and enriched by
PCR amplification, after which the library products were
sequenced using BGIseq-500. The KEGG pathway and
GO bioinformatics analyses were performed by the BGI,
using the Dr. TOM approach, an in-house customized
data mining system of the BGI. Altered (upregulated or
downregulated) expression of genes was expressed as
log2FC, which represents log-transformed fold change
(log2FC = log2[B] − log2[A], while A and B represent
values of gene expression for different treatment
conditions).Quantitative real-time PCR
After total RNA was extracted and mRNA purified,
mRNA was converted to cDNA using the Trans-
Scriptor First-Strand cDNA Synthesis SuperMix
(TransScript, #AT301, Beijing, China). The assays-
on-demand primers and probes and TaqMan Univer-
sal Master Mix were used to examine gene expres-
sion by the Roche LC480 Sequence Detection
System (TransStart) according to the user’s manual.
The house-keeping gene ACTB (encoding β-actin)
was used as internal control. All reactions were car-
ried out in triplicate and relative expression levels
were calculated as 2−△△CT after normalization to the
internal control. Each sample was analyzed inde-
pendently three times.Animal study
5 × 106 MOLM-13 cells were inoculated subcutane-
ously into nude mice. After 3 days, mice were ran-
domly divided into four groups (6 mice per group),
including vehicle (PBS) control, 30 mg/kg/days chida-
mide, 40 mg/kg/days MI-3, and both chidamide and
MI-3 by intraperitoneal injection and oral gavage, re-
spectively. Tumor size and body weight were mea-
sured daily. Mice were sacrificed after drug treatment
for 14 days when tumor size in any mice reached 20
mm3. All tumors was removed, measured, and
weighted. Tumor volume was calculated using the
formula V = 1/2(L × W2) (L:length, W:width). Histo-
logical examination was performed on tumor sections
after H&E staining.
Ye et al. Clinical Epigenetics          (2019) 11:137 Page 12 of 14Statistical analysis
Values represent the mean ± SEM for at least three in-
dependent experiments. All statistical analyses were car-
ried out using the SPSS 20.0 and GraphPad Prism 5.0
softwares. Variables between two groups were compared
using the two-tailed Student’s t test. Comparisons
among multiple groups were performed using the one-
way analysis of variance (ANOVA) followed by the
Bonferroni post hoc test. P < 0.05 was considered as sta-
tistically significant.
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